Wegovy, Saxenda and Zepbound are approved for weight loss in the following individuals: Adults with an initial BMI of 30, defined as obesity Adults with an initial BMI of 27, defined as overweight, with at least one weight-related comorbid condition Weight-related comorbid conditions include high blood pressure, cardiovascular disease (such as coronary artery disease, heart attack or heart failure), high cholesterol, obstructive sleep apnea, type 2 diabetes, fatty liver, GERD/acid reflux, osteoarthritis, urinary incontinence, etc
Lautenbach A, Wernecke M, Huber TB, Stoll F, Wagner J, Meyhfer SM, et al
Excess adiposity may further compound renal susceptibility and haemodynamic stress
With glutathione building blocks N-acetylcysteine (NAC) and glycine
Optimal timing for oral glutathione is days 46 of the tirzepatide injection cycle, taken on an empty stomach during morning fasting states to maximise small intestine exposure